Treatment Options for De Novo Metastatic Clear-cell Renal Cell Carcinoma: Current Recommendations and Future Insights.
Guidelines
Immunotherapy
Kidney cancer
Metastasis
Nephrectomy
Radiation therapy
Recommendations
Renal cell carcinoma
Targeted therapy
Journal
European urology oncology
ISSN: 2588-9311
Titre abrégé: Eur Urol Oncol
Pays: Netherlands
ID NLM: 101724904
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
01
06
2021
revised:
21
07
2021
accepted:
29
08
2021
pubmed:
18
9
2021
medline:
6
5
2022
entrez:
17
9
2021
Statut:
ppublish
Résumé
This clinical case-based discussion focuses on a 73-yr-old man diagnosed with intermediate-risk oligometastatic clear-cell renal cell carcinoma (RCC) and treated with systemic therapy. Current guideline-based treatment options are presented and critically examined. The discussion covers the main aspects of the management of metastatic RCC, such as the role of cytoreductive nephrectomy and metastasis-directed therapies, as well as the multiple options for systemic targeted and immune therapies. An insight into developments that may play a role in treatment pathways in the future according to the latest scientific advances is also provided. PATIENT SUMMARY: A number of treatment options are available for patients who have metastatic disease when diagnosed with clear-cell kidney cancer. Starting from a clinical case, the current standard of care and future perspectives regarding treatment of this disease are presented.
Identifiants
pubmed: 34531172
pii: S2588-9311(21)00150-4
doi: 10.1016/j.euo.2021.08.003
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
125-133Informations de copyright
Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.